An innovative research effort has revealed that administering stem cells to unborn babies diagnosed with spina bifida while undergoing fetal surgery could constitute a "major milestone" in treating birth defects.
Study Parameters and Security
The research conducted in the United States involved six developing infants with the 'open' form of spina bifida. Doctors administered regenerative cells sourced from the maternal placenta on the exposed area of the baby's spinal cord during the repair procedure.
Importantly, the stem cell application demonstrated a favorable safety profile. The study team reported that the therapy did not induce tumors, hinder surgical recovery, or prevent the reversal of related neurological issues.
Encouraging Results
Post-birth MRI scans indicated a successful correction of Chiari malformation in each of the babies. This favorable anatomical change is closely linked to improved motor skills and quality of life.
"In the event it allows more children to achieve ambulation who otherwise would not, then it would become the new treatment paradigm," said the lead researcher. "The results are extremely promising and open the door to numerous possible innovative interventions."
Future Implications and Hope
Experts not involved in the trial have suggested that subsequent studies of these apparent benefits could herald a "different age" in in-utero treatment. The possibility of ameliorating neurological damage present before birth is viewed as a paradigm-shifting aim.
Notably important would be better management of bladder and bowel function, which are typical difficulties for individuals living with this disorder.
Future Directions
Despite this being a first-in-human effort was small in scale, its confirmed tolerability and hopeful trends offer a robust platform for expanded clinical research. The addition of cellular treatment with current in-utero repair procedures holds considerable promise for improving the prognosis for babies yet to be born with spina bifida.